RecruitingPhase 4NCT02472028

Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals

LEukoaraiosis and blOod Pressure Reduction in OLD People

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

820 participants

Start Date

Sep 1, 2015

Study Type

INTERVENTIONAL

Conditions

Cerebrovascular Disorders

Summary

The purpose of the study is to test the hypothesis of slowing the progression of White Matter Lesions (WML) by lowering blood pressure (BP) in patients with cognitive complaints and a moderate to high grade of WML on brain MRI.

Eligibility

Min Age: 60 YearsMax Age: 88 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying blood pressure lowering algorithm and usual strategy for people with cerebrovascular disorders. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 60 Years to 88 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERblood pressure lowering algorithm

The treatments used in the "enhanced strategy" arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study.

OTHERusual strategy

The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.